Episode 5:
A New Look at LSD
A New Look at LSD
BY ERIN YOUNG
Hippies, a war on drugs, and a whole lot of stigma; LSD has been villainized for decades, but there’s research to support the use of LSD as a therapeutic treatment in addiction, depression, and other mental illnesses. “Turn on and tune in” to look at the history of LSD in the US and what LSD does in the brain.
This episode was produced as part of an upper level course on Neuropharmacology taught by Angel Kaur during Fall 2016 at UNC Asheville.
Articles Referenced
- De Gregorio, D.; Posa, L.; Ocha-Sanchez, R.; et al. The Hallucinogen D-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2, and TAAR1 receptors. Pharmacological Research. 2016, 113, 81-91.
Fantegrossi, W.E.; Murane, K.S.; Reissig, C.J. The behavioral pharmacology of hallucinogens. Biochemical Pharmacology. 2008, 75, 17-33.
Das, S.; Barnwal, P.; Ramasamy, A.; et al. Lysergic acid diethylamide: a drug of ‘use’? Ther Adv Psychopharmacol. 2016, 6, 214-228.
Schindler, E.A.D.; Dave, K.D.; Smolock, E.M.; et al. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacology, Biochemistry, & Behavior. 2012, 101, 69-76.
Chang, C., Liu, Z., Chen, M.C., Liu, X., and Duyn, J.H. (2013). EEG correlates of time-varying BOLD functional connectivity. Neuroimage. 2013, 72, 227–236.
Carhart-Harris, R.L.; et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr. Bull. 2013, 39, 1343–1351.
Nichols, D.E. Hallucinogens. Pharmacology and Therapeutics. 2004, 101, 131-181.
Lebedev, A.V.; et al. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum. Brain Mapp. 2015, 36, 3137–3153.
Tomasi, D.; Volkow, N.D.; Functional connectivity density mapping. Proc. Natl. Acad. Sci. 2010, 107, 9885–9890.
Bogenschutz, M.P.; Johnson, M.W. Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2016, 64, 250-258.
Vale, A. Drugs of abuse (amphetamines, BZP, cannabis, cocaine, GHB, LSD). Medicine. 2012, 40, 84-87.
Karaki, S.; Becamel, C.; Murat, S.; et al. Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Non-hallucinogenic Agonists. Molec. Cell. Proteomics. 2014, 13, 1273-1285.
Palhano-Fontes, F.; et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS ONE. 2015, 10, e0118143.
Studerus, E.; Gamma, A.; Vollenweider, F.X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. 2010, 5, e12412.
Tagliazucchi, E.; et al. Increased Global Functional Connectivity correlates with LSD-induced Ego Dissolution. Curr. Biol. 2016, 26, 1043-1050.
Carhart-Harris, R.L.; et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front. Hum. Neurosci. 2014, 8, 20.
Carhart-Harris, R.L; et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl. Acad. Sci. 2012, 109, 2138–2143.
Related Reading
Episode Transcript (forthcoming)
Credits
Written, Directed, Edited, and Featuring: Erin Young
Scientific Research by: Erin Young
Web Content by: Rosanna Garris
Sound Clips:
*LSD’s Long, Strange Trip. Retro Report. The New York Times. May 2016.
*NBC Universal Archives.
New episodes
New episodes arrive every third Tuesday